Skip to main content
Erschienen in: Drug Safety 3/2016

01.03.2016 | Original Research Article

A Method for the Minimization of Competition Bias in Signal Detection from Spontaneous Reporting Databases

verfasst von: Mickael Arnaud, Francesco Salvo, Ismaïl Ahmed, Philip Robinson, Nicholas Moore, Bernard Bégaud, Pascale Tubert-Bitter, Antoine Pariente

Erschienen in: Drug Safety | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The two methods for minimizing competition bias in signal of disproportionate reporting (SDR) detection—masking factor (MF) and masking ratio (MR)—have focused on the strength of disproportionality for identifying competitors and have been tested using competitors at the drug level.

Objectives

The aim of this study was to develop a method that relies on identifying competitors by considering the proportion of reports of adverse events (AEs) that mention the drug class at an adequate level of drug grouping to increase sensitivity (Se) for SDR unmasking, and its comparison with MF and MR.

Methods

Reports in the French spontaneous reporting database between 2000 and 2005 were selected. Five AEs were considered: myocardial infarction, pancreatitis, aplastic anemia, convulsions, and gastrointestinal bleeding; related reports were retrieved using standardized Medical Dictionary for Regulatory Activities (MedDRA®) queries. Potential competitors of AEs were identified using the developed method, i.e. Competition Index (ComIn), as well as MF and MR. All three methods were tested according to Anatomical Therapeutic Chemical (ATC) classification levels 2–5. For each AE, SDR detection was performed, first in the complete database, and second after removing reports mentioning competitors; SDRs only detected after the removal were unmasked. All unmasked SDRs were validated using the Summary of Product Characteristics, and constituted the reference dataset used for computing the performance for SDR unmasking (area under the curve [AUC], Se).

Results

Performance of the ComIn was highest when considering competitors at ATC level 3 (AUC: 62 %; Se: 52 %); similar results were obtained with MF and MR.

Conclusion

The ComIn could greatly minimize the competition bias in SDR detection. Further study using a larger dataset is needed.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Moore N. The past, present and perhaps future of pharmacovigilance: homage to Folke Sjoqvist. Eur J Clin Pharmacol. 2013;69:33–41.CrossRefPubMed Moore N. The past, present and perhaps future of pharmacovigilance: homage to Folke Sjoqvist. Eur J Clin Pharmacol. 2013;69:33–41.CrossRefPubMed
2.
Zurück zum Zitat Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf. 2007;30:891–8.CrossRefPubMed Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf. 2007;30:891–8.CrossRefPubMed
3.
Zurück zum Zitat Gould A. Practical pharmacovigilance analysis strategies. Pharmacoepidemiol Drug Saf. 2003;12:559–74.CrossRefPubMed Gould A. Practical pharmacovigilance analysis strategies. Pharmacoepidemiol Drug Saf. 2003;12:559–74.CrossRefPubMed
4.
Zurück zum Zitat Hauben M, Madigan D, Gerrits CM, Walsh L, Van Puijenbroek EP. The role of data mining in pharmacovigilance. Expert Opin Drug Saf. 2005;4:929–48.CrossRefPubMed Hauben M, Madigan D, Gerrits CM, Walsh L, Van Puijenbroek EP. The role of data mining in pharmacovigilance. Expert Opin Drug Saf. 2005;4:929–48.CrossRefPubMed
5.
Zurück zum Zitat Pariente A, Didailler M, Avillach P, Miremont-Salamé G, Fourrier-Reglat A, Haramburu F, et al. A potential competition bias in the detection of safety signals from spontaneous reporting databases. Pharmacoepidemiol Drug Saf. 2010;19:1166–71.CrossRefPubMed Pariente A, Didailler M, Avillach P, Miremont-Salamé G, Fourrier-Reglat A, Haramburu F, et al. A potential competition bias in the detection of safety signals from spontaneous reporting databases. Pharmacoepidemiol Drug Saf. 2010;19:1166–71.CrossRefPubMed
6.
Zurück zum Zitat Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483–6.CrossRefPubMed Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483–6.CrossRefPubMed
7.
Zurück zum Zitat Juhlin K, Ye X, Star K, Norén GN. Outlier removal to uncover patterns in adverse drug reaction surveillance—a simple unmasking strategy. Pharmacoepidemiol Drug Saf. 2013;22:1119–29.PubMed Juhlin K, Ye X, Star K, Norén GN. Outlier removal to uncover patterns in adverse drug reaction surveillance—a simple unmasking strategy. Pharmacoepidemiol Drug Saf. 2013;22:1119–29.PubMed
8.
Zurück zum Zitat Maignen F, Hauben M, Hung E, Holle LV, Dogne J-M. A conceptual approach to the masking effect of measures of disproportionality. Pharmacoepidemiol Drug Saf. 2014;23:208–17.CrossRefPubMed Maignen F, Hauben M, Hung E, Holle LV, Dogne J-M. A conceptual approach to the masking effect of measures of disproportionality. Pharmacoepidemiol Drug Saf. 2014;23:208–17.CrossRefPubMed
9.
Zurück zum Zitat Pariente A, Avillach P, Salvo F, Thiessard F, Miremont-Salamé G, Fourrier-Reglat A, et al. Effect of competition bias in safety signal generation. Drug Saf. 2012;35:855–64.CrossRefPubMed Pariente A, Avillach P, Salvo F, Thiessard F, Miremont-Salamé G, Fourrier-Reglat A, et al. Effect of competition bias in safety signal generation. Drug Saf. 2012;35:855–64.CrossRefPubMed
10.
Zurück zum Zitat Salvo F, Raschi E, Moretti U, Chiarolanza A, Fourrier-Réglat A, Moore N, et al. Pharmacological prioritisation of signals of disproportionate reporting: proposal of an algorithm and pilot evaluation. Eur J Clin Pharmacol. 2014;70:617–25.CrossRefPubMed Salvo F, Raschi E, Moretti U, Chiarolanza A, Fourrier-Réglat A, Moore N, et al. Pharmacological prioritisation of signals of disproportionate reporting: proposal of an algorithm and pilot evaluation. Eur J Clin Pharmacol. 2014;70:617–25.CrossRefPubMed
11.
Zurück zum Zitat Maignen F, Hauben M, Hung E, Van Holle L, Dogne J-M. Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases. Pharmacoepidemiol Drug Saf. 2014;23:195–207.CrossRefPubMed Maignen F, Hauben M, Hung E, Van Holle L, Dogne J-M. Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases. Pharmacoepidemiol Drug Saf. 2014;23:195–207.CrossRefPubMed
12.
Zurück zum Zitat Salvo F, Raschi E, Moretti U, Chiarolanza A, Fourrier-Réglat A, Moore N, et al. Pharmacological prioritisation of signals of disproportionate reporting: proposal of an algorithm and pilot evaluation. Eur J Clin Pharmacol. 2014;70:617–25.CrossRefPubMed Salvo F, Raschi E, Moretti U, Chiarolanza A, Fourrier-Réglat A, Moore N, et al. Pharmacological prioritisation of signals of disproportionate reporting: proposal of an algorithm and pilot evaluation. Eur J Clin Pharmacol. 2014;70:617–25.CrossRefPubMed
13.
Zurück zum Zitat Trifiro G, Pariente A, Coloma PM, Kors JA, Polimeni G, Miremont-Salamé G, et al. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiol Drug Saf. 2009;18:1176–84.CrossRefPubMed Trifiro G, Pariente A, Coloma PM, Kors JA, Polimeni G, Miremont-Salamé G, et al. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiol Drug Saf. 2009;18:1176–84.CrossRefPubMed
15.
Zurück zum Zitat Vidal 2014: le dictionnaire. 90e ed. Issy-les-Moulineaux: Vidal; 2014. Vidal 2014: le dictionnaire. 90e ed. Issy-les-Moulineaux: Vidal; 2014.
16.
Zurück zum Zitat Cantor SB, Kattan MW. Determining the area under the ROC curve for a binary diagnostic test. Med Decis Making. 2000;20:468–70.CrossRefPubMed Cantor SB, Kattan MW. Determining the area under the ROC curve for a binary diagnostic test. Med Decis Making. 2000;20:468–70.CrossRefPubMed
17.
Zurück zum Zitat Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29–36.CrossRefPubMed Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29–36.CrossRefPubMed
18.
Zurück zum Zitat van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11:3–10.CrossRefPubMed van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11:3–10.CrossRefPubMed
19.
Zurück zum Zitat Géniaux H, Assaf D, Miremont-Salamé G, Raspaud B, Gouverneur A, Robinson P, et al. Performance of the standardised MedDRA® queries for case retrieval in the French spontaneous reporting database. Drug Saf. 2014;37:537–42.CrossRefPubMed Géniaux H, Assaf D, Miremont-Salamé G, Raspaud B, Gouverneur A, Robinson P, et al. Performance of the standardised MedDRA® queries for case retrieval in the French spontaneous reporting database. Drug Saf. 2014;37:537–42.CrossRefPubMed
20.
Zurück zum Zitat Moore N, Kreft-Jais C, Haramburu F, Noblet C, Andrejak M, Ollagnier M, et al. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol. 2003;44:513–8.CrossRef Moore N, Kreft-Jais C, Haramburu F, Noblet C, Andrejak M, Ollagnier M, et al. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol. 2003;44:513–8.CrossRef
21.
Zurück zum Zitat Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54:315–21.CrossRefPubMed Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54:315–21.CrossRefPubMed
22.
Zurück zum Zitat DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat. 1999;53:177–89. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat. 1999;53:177–89.
23.
Zurück zum Zitat Ahmed I, Thiessard F, Miremont-Salame G, Haramburu F, Kreft-Jais C, Bégaud B, et al. Early detection of pharmacovigilance signals with automated methods based on false discovery rates. Drug Saf. 2012;35:495–506.CrossRefPubMed Ahmed I, Thiessard F, Miremont-Salame G, Haramburu F, Kreft-Jais C, Bégaud B, et al. Early detection of pharmacovigilance signals with automated methods based on false discovery rates. Drug Saf. 2012;35:495–506.CrossRefPubMed
24.
Zurück zum Zitat Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a reference set to support methodological research in drug safety. Drug Saf. 2013;36:33–47.CrossRef Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a reference set to support methodological research in drug safety. Drug Saf. 2013;36:33–47.CrossRef
Metadaten
Titel
A Method for the Minimization of Competition Bias in Signal Detection from Spontaneous Reporting Databases
verfasst von
Mickael Arnaud
Francesco Salvo
Ismaïl Ahmed
Philip Robinson
Nicholas Moore
Bernard Bégaud
Pascale Tubert-Bitter
Antoine Pariente
Publikationsdatum
01.03.2016
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 3/2016
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-015-0375-8

Weitere Artikel der Ausgabe 3/2016

Drug Safety 3/2016 Zur Ausgabe